drugset / Trial / NCT00389233

A Phase III Trial to Assess the Efficacy, Acceptability and Safety of Moviprep® Versus a 4L PEG+E Standard Solution

NCT00389233 ↗

Phase 3 Completed 360 enrolled Norgine
RandomizedParallel-groupSingle-blindTreatment

Summary

The study was carried out as a randomised, single-blind, active-controlled, multi-centric, phase III study with two parallel treatment groups. The primary efficacy criterion was the frequency of effective gut cleansing in each of the two treatment groups (grade A or B "overall quality of gut cleansing" as judged by a blinded expert panel on the basis of videotapes recorded during the endoscopic procedure).

Timeline

Start
2002-06
Primary completion
—
Completion
2002-12

Outcome

Met primary endpoint

paper The difference fell within the predefined limit for noninferiority. PMID 18190651 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject NRL994 Unknown 1000 ml Oral
Comparator PEG + E Unknown 2000 ml Oral

Indications

No indication recorded.